HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 6,841-6,852 of 27,277
Drug study icon
CompletedNCT06842992

A Phase II Study to Evaluate NH102 for Depression

What is this study about?

This study evaluated the safety and effectiveness of NH102 for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Hefei
DepressionMedication studyAges 18–65
Countries
China
Sponsor
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Drug study icon
CompletedEUCTR 2021-003154-23

A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Croatia
PTSDHistorical research record
Countries
Croatia, Finland, Poland, + 1 other
Sponsor
Boehringer Ingelheim AB
Drug study icon
CompletedNCT01886469

A Phase II, Adaptive study Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Official study title

A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.

This study has finished and is no longer accepting participants.

In Saskatoon
ADHDMedication studyAges 6–17
Countries
Canada
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Drug study icon
Active Not RecruitingNCT05733546

COMP360 for recurrent depression: safety and tolerability

About this title

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Read the official source — NCT05733546
Official study title

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

This study is no longer accepting new participants.

Multiple locations, including La Jolla
DepressionMedication studyAges 18+
Countries
United States
Sponsor
COMPASS Pathways
Drug study icon
CompletedEUCTR 2015-000222-11

A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependen...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In United Kingdom
AddictionHistorical research record
Countries
United Kingdom
Sponsor
University College London
Drug study icon
CompletedEUCTR 2021-002093-34

A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Italy
Mental healthHistorical research record
Countries
Italy
Sponsor
NEWRON PHARMACEUTICALS SPA
Drug study icon
CompletedEUCTR 2010-021984-33

A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exa...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Slovakia
SchizophreniaHistorical research record
Countries
Slovakia
Sponsor
F. Hoffmann-La Roche Ltd
Drug study icon
CompletedEUCTR 2011-005200-15

A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Finland
DepressionHistorical research record
Countries
Finland, Germany, Norway, + 1 other
Sponsor
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Drug study icon
CompletedEUCTR 2020-003760-11

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Germany
SchizophreniaHistorical research record
Countries
Germany, Italy, Norway, + 2 others
Sponsor
Boehringer Ingelheim Pharma GmbH & Co. KG

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.